The Global Health Body Sounds Concern Over Critical Scarcity of Obesity Medications
Fewer than 10% of patients eligible to benefit from GLP-1 drugs like Wegovy can access them, warns the World Health Organization as it publishes its first guidance on the medications.
With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is urging broader and more equitable availability to this class of drugs.
Per forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"The latest guidelines affirms that excess weight is a chronic disease that can be managed with holistic and ongoing treatment," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are key hurdles to widespread access to the jabs that can help people shift considerable body mass, says the body.
GLP-1 Therapy Supply Crisis
Even under the current most optimistic scenario, the production of GLP-1 therapies could only cover around 100 million people – under 10% of the global need, as stated by the WHO.
The recommendation calls on nations and manufacturers to increase access, via approaches such as voluntary licensing.
Exclusive production rights on the active ingredient – the primary component of the drug Wegovy – is scheduled to end in multiple nations in 2026.
How Weight-Loss Jabs Operate
GLP-1 drugs replicate a body's own hormone to delay gastric emptying, suppress the appetite and boost feelings of fullness so people consume fewer calories.
Individuals usually see weight reduction after several weeks of beginning the once-weekly jabs.
Research points to patients may put most of the weight back on within a year of stopping the drug, when their normal hunger resume.
To be carrying excess weight increases your risk for developing health problems, like type 2 diabetes, cardiovascular issues, stroke, and some cancers.
Obesity affects individuals in all nations and was linked to millions of fatalities worldwide in 2024, per the WHO.
